Plasma microRNA expression levels and their targeted pathways in patients with major depressive disorder who are responsive to duloxetine treatment
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 110, 38-44
Abstract
No abstract availableKeywords
Funding Information
- Ontario Brain Institute
This publication has 36 references indexed in Scilit:
- Increased pregenual anterior cingulate glucose and lactate concentrations in major depressive disorderMolecular Psychiatry, 2016
- Comparison of plasma MicroRNA levels in drug naive, first episode depressed patients and healthy controlsJournal of Psychiatric Research, 2015
- NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorderBrain, Behavior, and Immunity, 2014
- New insight in expression, transport, and secretion of brain-derived neurotrophic factor: Implications in brain-related diseasesWorld Journal of Biological Chemistry, 2014
- Blood microRNA changes in depressed patients during antidepressant treatmentEuropean Neuropsychopharmacology, 2013
- Inflammatory and Neurodegenerative Pathways in Depression: A New Avenue for Antidepressant Development?Current Medicinal Chemistry, 2011
- What causes the hippocampal volume decrease in depression?European Archives of Psychiatry and Clinical Neuroscience, 2007
- Gene Ontology: tool for the unification of biologyNature Genetics, 2000
- Reduction of Prefrontal Cortex Glucose Metabolism Common to Three Types of DepressionArchives of General Psychiatry, 1989
- Frontal cortex and basal ganglia metabolic rates assessed by positron emission tomography with [18F]2-deoxyglucose in affective illnessJournal of Affective Disorders, 1986